Literature DB >> 8530331

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

S S Rich1, J H Friedman, B R Ott.   

Abstract

BACKGROUND: We report six cases of psychosis in patients with akinetic-rigid syndromes who were treated with risperidone.
RESULTS: Five of the six patients experienced intolerable exacerbation of parkinsonism. Four subsequently did well on clozapine therapy. One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine. Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment; the encephalopathy resolved when the patients were switched to clozapine treatment. Only one patient, the youngest, did well on risperidone therapy.
CONCLUSION: We believe that risperidone is not a substitute for clozapine in treating psychosis in parkinsonian patients and should be used with caution.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530331

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  26 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 2.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

Review 3.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

Review 4.  Diagnosis and treatment of psychotic symptoms in elderly patients.

Authors:  J T Lake; A H Rahman; G T Grossberg
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

Review 5.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 6.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 7.  Geriatric psychosis.

Authors:  J P Lacro; D V Jeste
Journal:  Psychiatr Q       Date:  1997

8.  Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report.

Authors:  Bruno Fukelmann Guedes; Marcia Rubia Gonçalves; Rubens Gisbert Cury
Journal:  Dement Neuropsychol       Date:  2016 Apr-Jun

9.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 10.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.